Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 10/20 | 0.78 |
| ▸ | CA12 | O43570 | 9/20 | 0.64 |
| ▸ | ALPI | P09923 | 2/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | ALPL | P05186 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10533060 | 0.83 | CA2 (0.77) | CA2CA12ALPICHRNB4CHRNA3 | |
| SCHEMBL1919685 | 0.77 | CA2 (0.52) | CA2CA12MRGPRX4CYP2A6FDFT1 | |
| SCHEMBL3791638 | 0.76 | CA2 (0.51) | CA2CA12CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL28194347 | 0.74 | CA2 (0.61) | CA2CA12CYP2A6 | |
| SCHEMBL827016 | 0.73 | CHRNB4 (0.56) | CA2CA12CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL17541419 | 0.73 | MRGPRX4 (0.47) | CA2CA12CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3541660 | 0.73 | CHRNB4 (0.56) | CA2CA12CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL826624 | 0.73 | CYP2A6 (0.55) | CA2CA12CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL576200 | 0.72 | MMP2 (0.55) | CA2CA12ALPIALPL | |
| SCHEMBL3791985 | 0.71 | CA2 (0.47) | CA2CA12CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3388425-B1 | AMINOAZOLE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2020-08-05 | — | — | EP | disclosed |
| US-10689354-B2 | Aminoazole derivative | TEIJIN PHARMA LIMITED (JP) | 2020-06-23 | — | — | US | disclosed |
| US-20190031628-A1 | AMINOAZOLE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2019-01-31 | — | — | US | disclosed |
| EP-3388425-A1 | AMINOAZOLE DERIVATIVE | Teijin Pharma Limited (JP) | 2018-10-17 | — | — | EP | disclosed |
| CN-1277472-C | Selective herbicides comprising tetrazolinone derivatives | BAYER CROPSCIENCE AG (DE) | 2006-10-04 | — | — | CN | disclosed |
| CN-1575128-A | Selective herbicides comprising tetrazolinone derivatives | BAYER CROPSCIENCE AG (DE) | 2005-02-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689354-B2 | Aminoazole derivative | AR, NR3C2, NR5A1 | CA2 1404/4885CA12 715/4885ALPI 4579/4885 |
| US-20190031628-A1 | AMINOAZOLE DERIVATIVE | AR, NR3C2, NR5A1 | CA2 1404/4885CA12 715/4885ALPI 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.